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ABSTRACT 
 
Background: There is little consensus regarding the need for vitamin and mineral 
supplementation during pregnancy. The composition and use of supplements among 
pregnant women varies greatly. Toxicity or inadequacy of nutrients could have health 
effects on the mother and fetus. A recent study reported inadequate micronutrient 
consumption in United States pregnant women (1), supporting the need for 
supplementation. 
 
Objective: The purpose of this project is to determine the frequency of supplementation 
among a sample of low to middle-class pregnant women in the Kansas City 
metropolitan area and determine if consumed supplements favor the Institute of 
Medicine’s Recommended Daily Allowance (RDA) guidelines. 
 
Design: A subset of women (n=231) enrolled in a phase III clinical trial from 2006-2010 
provided information regarding use of supplements. Nutrient intakes during pregnancy 
are reported as means ± SD. One way ANOVAs and Pearson Chi Square tests were 
also used for other analyses.  
 
Results: Women reported consuming a nutritional supplement before, during or after 
pregnancy were 50%, 100%, and 35%, respectively. Supplement use before pregnancy 
was impacted by previously known cofactors. Mean micronutrient intake from 
supplements was below the RDA or AI for vitamin D, calcium, and iron, while vitamin C 
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and folic acid were found to be excessive. Median intakes of choline and iodine were 
zero. 
 
Conclusions: Supplementation during pregnancy was common in this cohort but 
individual formulations varied. As a public health message, it would be beneficial for 
formulations of prenatal supplements to be standardized to ensure women consume 
nutrients vital to the developing fetus.  
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Chapter 1 
INTRODUCTION 
During pregnancy the sole source of nutrition for the fetus is through the mother’s 
nutrient stores and daily dietary intake. Therefore, it is imperative the mother provide 
adequate nutrients for the developing fetus. Requirements for fourteen of the twenty-
one essential micronutrients are higher during pregnancy; and on the advice of their 
obstetricians, many women complement their dietary intake with supplements 
throughout pregnancy (2). However, the use of prenatal supplements among pregnant 
women varies greatly depending upon how frequently they take the supplements; the 
length of time they take the supplements; how closely they adhere to dosing 
instructions; and the formulation of supplements. Little research has been conducted in 
the United States regarding what supplements women are taking during pregnancy and 
most of the existing publications are quite old. Published findings do examine factors 
affecting compliance of supplement intake, but there is no current publication on what 
women are taking during pregnancy and how this affects their nutritional status. While 
supplementation of prenatal vitamins and minerals is not recommended by the Institute 
of Medicine for every pregnant woman, emerging research shows the benefits of 
supplementation (3). 
Statement of purpose 
The purpose of this project is to determine the intake of key nutrients recognized 
as commonly inadequate in the diet of US pregnant women by evaluating both the 
composition and frequency of supplement intake. 
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Research questions 
Primary research question: 
How much vitamin C, vitamin D, vitamin E, folic acid, calcium, iron, iodine, and 
choline did women receive from prenatal supplements during pregnancy? 
Secondary research questions: 
1. In addition to prenatal vitamins, what other supplements are being consumed? 
2. What demographic differences exist between women who took supplements 
before pregnancy and those who did not?   
3. Is post-natal supplementation related to breastfeeding? 
4. Is there a difference between over-the-counter prenatal formulations and 
prescription prenatal formulations? 
 
3 
 
Chapter 2 
LITERATURE REVIEW 
Dietary supplement intake in pregnancy 
Publications regarding prenatal supplement use date back to early 80’s and often 
only examine factors affecting capsule compliance. Advances in medicine and 
pharmacology as well as maternal education regarding prenatal care suggest changes 
in supplementation are to be expected but none are documented. It is believed that 
most healthcare providers recommend consuming a prenatal multivitamin and 
multimineral during pregnancy although there is little evidence to support the need for 
supplementation in developed countries such as the United States. Prenatal 
multivitamin use did decrease the risk for fetal malformations in one study suggesting 
benefits may accrue to at least some women and their offspring (4).  
In 1988, the National Maternal and Infant Health Survey (NMIHS) found that 26% 
of women surveyed in the United States were taking a multivitamin supplement prior to 
pregnancy (5). A contemporary study culturally diverse, low-income women in the 
United States reports 16% were taking some multivitamin prior to conception, but not 
necessarily a prenatal supplement (6). In 2003, a study in Melbourne, Australia 
evaluated pregnant women between 36-38 weeks gestation to examine the vitamin use 
before and during pregnancy. The study found 11% of the women took a pre-pregnancy 
multivitamin and 36% started on the multivitamin without doctor’s recommendation, 
while 30% were recommended to do so by their primary care physician. During 
pregnancy, 34.7% of this cohort was taking prenatal multivitamins, although a variety of 
brands and doses were reported by subjects (7). 
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Prenatal supplementation recommendations during pregnancy 
Whether it is a multivitamin, folic acid, iron, or iodine supplementation, current 
recommendations of prenatal supplementation are not consistent. The Institute of 
Medicine (IOM) recommends general, prenatal supplementation only for women who 
smoke, abuse alcohol/drugs, have iron deficiency anemia, have poor quality diets, are 
vegans, and women with ≥2 fetuses (2, 8). The Centers for Disease Control and 
Prevention (CDC) and the IOM recommends all women of child bearing age who are 
capable of becoming pregnant, consume 0.4 mg/d folic acid. Once the pregnancy is 
confirmed, the CDC recommends oral, low dose iron, 30 mg/d beginning with the first 
prenatal visit (9). Conflicting recommendations from the World Health Organization 
(WHO) instruct iron supplementation of 60 mg/d for 6 months, or if 6 months of 
treatment cannot be achieved, continuation during postpartum or an increased dosage 
of 120 mg/d (10). It is important to note that WHO emphasizes their recommendations 
to poverty-stricken populations where access to good nutrition and iron-rich foods is 
limited. The American Thyroid Association recommends that all pregnant women living 
in North America consume 150 µg/d of iodine (11). 
Supplementation outcomes on birth 
Different types of supplementation have been associated with various birth 
outcomes and are often inconsistent. Scholl et al. (12) found that multivitamin use prior 
to conception has little influence on pregnancy outcome. A retrospective case-control 
study showed that use of a multivitamin from three months prior to conception through 
the third month of pregnancy decreased the risk of heart malformations in the fetus (4). 
In a randomized, controlled placebo-like trial with 4,862 subjects, antenatal multivitamin 
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supplementation was found to decrease the incidence of cardiovascular malformations 
((3, 13). 
Iron supplementation throughout pregnancy increased birth weight by 100-200 g, 
and when compared with a placebo, decreased the risk of low birth weight births (14). 
Iron supplementation during pregnancy increased birth weight by a mean of 103 g in a 
Zimbabwe study (15). A study conducted in Nepal, found iron supplementation 
decreased low birth weight by 16% (16). 
When multimicronutrient supplementation is compared to iron-folic acid only 
supplementation, multimicronutrient supplementation has been found to reduce the 
incidence of low birth weight babies by 17%. A meta-analysis found that newborn birth 
weight was 54 g higher among women supplemented with a multimicronutrient 
supplementation versus iron-folic acid supplementation only. However, the type of 
supplement did not change the risk of preterm or small-for- gestational-age birth (17).  
Scholl et al (18) found that low and marginal folate status was associated with 
increased risk of preterm delivery and low birth weight. Low maternal zinc status was 
also associated with low birth weight and preterm delivery. 
Supplementation outcomes on mothers 
The Camden Study examined maternal nutrition in Camden, New Jersey, one of 
the poorest cities in the United States. Prenatal supplements were associated with 
better prognostic indicators including better weight gain for gestation and less bleeding 
and nausea, etc. The Camden Study also found that the use of prenatal multivitamins 
during the 1st and 2nd trimesters resulted in a twofold reduction in the risk of preterm 
delivery; twofold reduction of a low birth weight baby; and decreased risk of a very 
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preterm delivery and a very low birth weight baby. Serum nutrient concentrations were 
also examined for ferritin, zinc and folate levels. At study entry, women who 
supplemented prior to conception differed little in nutrient status from women who did 
not supplement. By week 28, status of numerous micronutrients differed. Red cell and 
serum folate as well as ferritin were increased in the preconception supplement users. 
Zinc levels did not differ at week 28 between the preconception supplement users and 
the nonusers (12).   
In regard to folate status levels in particular, adequate serum folate is associated 
with appropriate gestational weight gain and duration of pregnancy (12). 
Current use of supplementation in the United States and abroad 
The categories of nutrient supplements consumed during pregnancy may be 
divided into four main categories: multivitamins, folic acid, iron and other which includes 
single nutrient supplementation such as vitamin C, zinc, calcium and pyridoxine. 
Folic acid is recommended to decrease the risk of congenital malformations 
including neural tube defects during pregnancy. One study in the United States targeted 
women who were attempting to conceive. Of the women who became pregnant, 44% 
took folic acid 3 months prior to conception. In the same study, 93% of the women were 
supplementing with  folic acid, at 11 weeks gestation (19). In the previously mentioned 
Australian study, 29% took folic acid during the periconception period. Greater than 
50% reported that it was recommended by their primary care physician, while 19% self-
prescribed, and 5% used supplementation at the recommendation of friends. During 
pregnancy, 80% of this population took folic acid (7).  
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Iron is another supplement often prescribed during pregnancy. National Health 
and Nutrition Examination Survey III (NHANES III) found 74% of pregnant women were 
taking iron supplements as a standalone nutrient. The mean iron intake from 
supplements was 78.4 ± 6.6 mg/d (20), which is greater than the IOM upper limit of 45 
mg/d (21). Fifty-one percent of the women in the Australian study took an iron 
supplement during pregnancy. Of the women who used an iron supplement, 46% did so 
to combat anemia, 14% used it to enhance energy, and 33% were otherwise 
recommended to do so by their physicians (7). 
Other single nutrient supplements reported to be taken pre-pregnancy in the 
Australian study included calcium, pyridoxine, and zinc. Calcium was taken by 44% of 
the subjects and was recommended primarily by physicians, but 21% of the women 
reported taking the supplement spontaneously. Pyridoxine was taken by 14% of the 
women, of which 48% reported taking it for morning sickness and nausea. Zinc was 
also supplemented in 7% of the women, taking the supplement for their own health and 
the health of the fetus (7). In 1988, the NMIHS found that expectant mothers took 
calcium, zinc, vitamin C, and vitamin A at least 3 times a week during the last three 
months of their pregnancy (5).  
Dietary supplement adherence in pregnancy 
Multiple factors have been associated with adherence to supplement intake by 
pregnant women. Studies have consistently shown that supplement intake during 
pregnancy is affected by ethnicity and race (5, 22). A study conducted by Suitor and 
Gardner (6) in a culturally diverse, low-income population found that white, non-
Hispanic pregnant women had higher rates of supplement usage (23%) compared to 
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Hispanic women (10%). Within the 1988 NMIHS, Yu et al. (5) found black mothers to be 
17% less likely than white mothers to take a multivitamin. Cultural differences in the 
non-Hispanic blacks may explain adherence differences when supplements are 
prescribed. Common misconceptions about the effects of supplements included 
increased weight gain, fear of complex labor due to macrosomia, fear of developing too 
much blood, and fear of deformities in babies (5). Lack of adherence to iron 
supplements is a particular concern in non-Hispanic blacks because they have a greater 
risk of iron deficiency anemia (22). 
Education and age are positively associated with supplement usage. Sixty-seven 
percent of women with ≤ 8 years of formal education used multivitamins during 
pregnancy compared to 89.9% of women with formal education ≥16 years, a 22.9% 
difference in use. Additionally, women ≤20 years old had a 65.5% adherence rate 
compared to women , 20-34 years old (82.4%) and those ≥35 years old (86.3%) (5).  
Socioeconomic status is also a common factor associated with supplementation 
use (6). The National Health Institute Survey (NHIS) found that women in households 
>200% above the poverty level were more likely to take supplements during pregnancy 
(23). NHANES III found women with socioeconomic status ≤130% poverty level were 
less likely to consume nutrient supplements during pregnancy (3). Women who received 
Medicaid for prenatal care were less likely to take supplements than women not 
receiving Medicaid (assumed to be insured or self-paying). Scholl et al. (12) reported 
85% of mothers on Medicaid did not use prenatal multivitamins. The United States 
Department of Agriculture 1985 Continuing Survey by Individuals, found that 40% of 
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women ≤130% below poverty level were taking supplements regularly or occasionally 
(6).  
The NHIS found that former smokers were more likely to use supplements (23). 
Yu et al. (5) found that smokers were more likely to take supplements during pregnancy, 
suggesting that this population may be potentially more mindful about adhering to health 
care advice to balance the harmful effects of smoking. White women in the iron 
supplementation study conducted by Jasti et al. (22) were found to adhere more closely 
to the regimen if they were current smokers. Jasti et al. (22) suggest that the higher 
adherence is due to an increased concern about pregnancy outcomes. 
Conclusion 
Supplementation during pregnancy varies greatly, and new recommendations 
are continually published based on emerging research. The current recommendations 
of prenatal supplementation vary among national organizations, as well as primary care 
providers, with little evidence supporting the use of prenatal supplementation, 
particularly in developed countries. It is important to examine the barriers to supplement 
intake adherence and how barriers such as race and ethnicity, education level, socio-
economic status, maternal age, and smoking status of prenatal care can be overcome. 
More research is also necessary to examine what pregnant women are taking for 
prenatal supplements and the outcomes of supplementation on birth in healthy mothers, 
particularly in the United States. It is not ethical to conduct a randomized trial among 
subjects with the limited evidence regarding supplementation outcomes on birth.  
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Chapter 3 
METHODS 
Overview 
Maternal supplement use during pregnancy is a secondary outcome of the KU 
DHA Outcome Study (KUDOS) conducted from 2006 to 2011 at the University of 
Kansas Medical Center in Kansas City, KS. The primary KUDOS study examined the 
efficacy and safety of docosahexaenoic (DHA) supplementation (600 mg/day) in 
pregnant women (NCT00266825). Supplementation was given for approximately the 
last two trimesters of pregnancy. Primary aims of the study were to: 1) determine 
whether maternal RBC PL DHA can be significantly increased by supplementation, 2) 
assess the effect of DHA supplementation on duration of gestation, 3) evaluate adverse 
events in women and infants in the treated and placebo groups, 4) evaluate the effect of 
maternal DHA supplementation on visual evoked potential acuity in infancy and 5) 
evaluate the effect of DHA supplementation on the development of fundamental 
measures of cognitive function in infancy. 
The Office of Dietary Supplements supported a study to examine what dietary 
supplements women take during pregnancy and the amounts of specific nutrients 
women receive during pregnancy from supplements. This analysis examined not only 
traditional prenatal vitamin and mineral supplement but also other non-traditional 
supplements. Supplement intake before, during and after pregnancy was examined as 
well as factors related to supplement intake.  
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Sample 
Women between the ages of 16 and 35.99 years who were between 8 and 20 
weeks gestation were eligible to participate in the study.  Study subjects agreed to 
consume capsules (DHA or placebo) from enrollment in the study until delivery of the 
infant and to be available by telephone. Participants also agreed to return to the study 
centers for delivery and postnatal infant follow-up visits. 
Exclusion criteria included any potential participants with serious health 
conditions likely to affect the growth and development of their fetus; the postnatal 
growth and development of their newborn; or the health of the mother during pregnancy. 
Serious health conditions included, but were not limited to, cancer, lupus, hepatitis, 
diabetes mellitus (Type I, Type II, or gestational), or HIV/AIDS. Multiple births were 
excluded due to the increased risk of preterm and low birth weight delivery. Women with 
morbid obesity (BMI ≥40) or elevated blood pressure (systolic ≥140 mmHg) were 
excluded. As not all postnatal developmental tests were standardized for different 
cultural groups; non-English speaking patients were also excluded.  
Research setting 
Women enrolled in the study (n=350) were primarily recruited from the University 
of Kansas Medical Center (Kansas City, Kansas), Truman Medical Center (Kansas City, 
Missouri), and St. Luke’s Hospital (Kansas City, Missouri). Some women enrolled were 
self-identified from clinicaltrials.gov, myKUMC email blast, and by word of mouth. 
Potential participants enrolled from clinics were approached at a prenatal appointment 
and the background, purpose, procedures, and risks of the study were explained. 
12 
 
All of the postnatal follow-up visits occurred at the University of Kansas Medical 
Center beginning on August 30, 2006. Women returned to the study center for follow-up 
of their infants when they were at 6 weeks, and 4,6,9,10,12, and 18 months.  
Ethics 
 Approval for the KUDOS study was obtained by the Institutional Review 
Board, protocol #10186. The study is currently under an existing protocol. Written 
informed consent was obtained (see Appendix A) and the welfare of study subjects was 
upheld according to the Helsinki Declaration. Confidentiality was ensured throughout 
the study. Names of subjects or other identifying information was not released without 
written consent. All subjects were assigned a random identification number.  Information 
was secured under lock and key and only approved study protocol members were 
allowed access to collected data.  Information was protected by the Health Insurance 
Portability and Accountability Act (HIPAA) which is a federal law to ensure privacy of 
health information.  
Procedures and materials 
 This sub-study design to determine supplement intake was a prospective cohort 
study. Subjects (n=348) were asked at enrollment what supplements they were 
currently taking, what they took prior to pregnancy, and what supplements were 
prescribed (see Appendix B). Data were recorded by the study personnel. Women still 
enrolled at the first postnatal visit follow-up visit (n=231) were asked again what 
supplements they took before, during and after pregnancy (see Appendix C). Data were 
again recorded by the study personnel. Beginning July 2009, subjects (n=76) were also 
sent a monthly supplement questionnaire during pregnancy (see Appendix D). A total of 
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178 questionnaires were collected. Information was gathered by reading the questions 
from the forms. The questionnaires were not standardized.  
In order to determine the length of time a supplement was taken, the start date 
reported on the initial enrollment questionnaire was utilized because it was presumed to 
be most accurate due to closer proximity to the actual start date. If no start date was 
indicated on the enrollment questionnaire, the start date from the 6 week follow-up visit 
was utilized. The stop date used was reported at the 6 week infant visit or if ongoing, 
subsequent clinic visits. For example, if the mother was still taking the prenatal 
supplement at 6 weeks, 4, 6, and 9 months, but reported the stop date at the 12 month 
visit, that date would be used. If no stop date was specified, in the case a subject 
dropped from the study, the stop date was assumed to be the date of delivery.  
 Study personnel captured supplement brand names when possible. If a brand 
name was reported at enrollment, but at the 6 week follow-up the subject was unsure, it 
was assumed to be the same supplement as reported at enrollment. Some assumptions 
were made regarding the formulation of the products. For example, if a woman reported 
taking an over-the-counter prenatal, but was unsure of the name, average over-the-
counter nutrient amounts were assigned. The most frequently consumed over-the-
counter supplements had identical compositions and therefore were used when the 
brand name was unknown. If women reported unknown prescription prenatals (n=21) 
we removed them from the analyses, there was no common formulation for prescription 
prenatal supplements. In many cases women changed prenatal supplements during 
pregnancy. If data overlapped, we assumed that the initial prenatal was taken until the 
second supplement began. 
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Frequency of supplementation was best assessed from the women receiving the 
monthly questionnaires. If the reporting varied on the questionnaires, an average was 
taken. For women without the monthly questionnaires, frequency reported at the 6 week 
clinic visit was used. When frequency was not reported (n=2), the subject was not 
included in the analysis. One subject was excluded for nutrient analysis due to 
excessive frequency report of prescription prenatal supplements.  
 Supplementation after pregnancy was considered to be any supplement taken at 
least 30 days after pregnancy ended. Anything less than 30 days did not qualify.  
 When assessing nutrient intake, eight nutrients were chosen. Vitamin C, vitamin 
D, vitamin E, folic acid, calcium,  and iron were used by recommendation from the 
R03NR008458-01 NIH-funded study, whose purpose was to develop a profile of 
common nutritional patterns among pregnant African American women (1). In addition, 
iodine and choline were analyzed due to emerging interest in pregnancy. DHA was 
recorded, however, the study selected against women consuming >300 mg DHA/day 
because it was designed to compare DHA supplementation to placebo. 
Statistical analysis 
Nutrient intakes during pregnancy are reported as means ± SD.  Differences in 
specific nutrient contents between prescribed and over-the-counter pre-natal vitamins 
were assessed using a one-way ANOVA.  Women electing to take pre-natal vitamins 
prior to conception were compared to their peers with regard to smoking status, 
maternal age at enrollment, and race.  Differences in smoking status and maternal age 
were determined using one-way ANOVA, while comparisons of maternal race were 
analyzed with a Pearson Chi-Square test for categorical variables.  One-way ANOVA 
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was also used to assess differences in length of breastfeeding between women electing 
to consume and those who refrained from consuming vitamins postnatally.  All data 
were analyzed with SPSS Statistics 17.0 software (SPSS, Chicago, IL), and a P-value ≤ 
0.05 was considered significant.   
Data collection 
 Data collection was completed via questionnaires previously described and 
entered in the Microsoft Access® database (Appendices A-D). The type and frequency 
of supplements was recorded for each subject. An additional database was established 
with all the supplements taken by subjects as well the amount of nutrients within each 
supplement type. Prenatal formulations were collected by a combination of internet 
searches and store visits to determine supplement formulation.  
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Chapter 4 
RESULTS 
Nutrient intake during pregnancy from prenatal vitamins 
Nutrient intake for nine micronutrients was calculated by total intake during pregnancy 
and intake per pregnancy day. Length of supplementation and frequency were taken 
into account in the analysis. Average frequency of supplementation was 0.997 
supplements per day.  Table 1 summarizes the total nutrient intake during pregnancy. 
Table 2 summarizes total nutrient intake per pregnancy day. Figures 1-12 outline the 
individual nutrient intakes per pregnancy and per pregnancy day. Iodine, Choline and 
DHA were not consumed by many women, thus medians were calculated rather than 
means.  
TABLE 1: Total Nutrient Intake During Pregnancy (n=203) 
 Mean Standard Deviation Range 
Vitamin C (mg) 25,681 8,749 1,509 - 57,840 
Vitamin D (IU) 91,197 33,601 10,057 - 253,000 
Vitamin E (IU) 6,423 3,715 616 - 27,500 
Folic Acid (µg) 189,703 62,224 17,200 – 385,600 
Calcium (mg) 46,549 19,537 0 - 144,600 
Iron (mg) 6,254 2,510 704 - 21,330 
 
TABLE 2: Nutrient Intake Per Pregnancy Day (n=203) 
 Mean Standard Deviation Range 
Vitamin C (mg) 94 31 6 - 207 
Vitamin D (IU) 333 119 37 - 917 
Vitamin E (IU) 23 13 2 - 100 
Folic Acid ( µg ) 693 209 60 - 1,382 
Calcium (mg) 170 69 0 - 518 
Iron (mg) 23 9 3 - 74 
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Mean = 25,681 
Std. Dev. = 8,749 
N=203 
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Mean = 94 
Std. Dev. = 31 
N=203 
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Mean = 91,197 
Std. Dev. = 33,601 
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Mean = 333 
Std. Dev. = 119 
N=203 
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Mean = 6,423 
Std. Dev. = 3,715 
N=203 
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Mean = 23 
Std. Dev. = 13 
N=203 
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Mean = 189,703 
Std. Dev. = 59,300 
N=203 
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Mean = 693 
Std. Dev. = 209 
N=203 
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Mean = 46,549 
Std. Dev. = 19,537 
N=203 
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Mean = 170 
Std. Dev. = 69 
N=203 
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Mean = 6,254 
Std. Dev. = 2,510 
N=203 
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Mean = 23 
Std. Dev. = 9 
N=203 
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The mean intake of vitamin C was 94 mg per day, while the RDA is 85 mg per 
day. The maximum intake was 207 mg per day.  
The RDA for vitamin D is set at 600 IU per day, while the mean intake was 333 
IU per day. However, maximum intake from our subjects was 917 IU per day, which is 
far from the UL of 4,000 IU per day. 
Vitamin E mean intake from supplements was 23 IU per day, meeting 100% of 
the RDA. Maximum intake was 100 IU per day. 
The mean intake of folic acid was 693 μg per day, exceeding the RDA of 600 µg. 
Maximum intake was 1,328 μg per day. Nine subjects (4%) supplemented with 
additional folic acid as a single nutrient during pregnancy. The UL for folic acid is set at 
1 mg per day. 
Mean intake of calcium was 170 mg per day with the RDA set at 1,000 mg per 
day. The highest reported intake from supplements was 518 mg per day. 
The RDA for iron is set at 27 mg per day. Mean iron intake was 23 mg per day 
with the maximum intake was 74 mg per day. 
Median intakes were calculated for the three emerging nutrients: iodine, choline 
and DHA. Median intake for all three nutrients was zero. Iodine was found in 43% of 
prenatal supplements (16/37), with amounts ranging from 0-290 µg. The RDA is set at 
220 µg. Choline was found in 19% (7/37) of prenatal supplements, with amounts 
ranging from 0-60 mg. The RDA for choline is set at 450 mg per day.  DHA was found in 
30% of the supplements (11/37), ranging from 0-300 mg. No RDA has been established 
for DHA.  
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Other single nutrient supplements consumed during pregnancy included 
additional DHA and folic acid in addition to that provided by the prenatal or multivitamin. 
Women who consumed DHA supplements consumed an average of 230 mg per day 
(n=20).  Additional folic acid was taken during pregnancy (n=9), but specific nutrient 
amounts could not be determined.  
Supplement intake prior to pregnancy 
 Women who took supplements prior to pregnancy compared to those that did not 
had different income by zip code of residence at the time of enrollment, maternal 
education, maternal age, maternal race and smoking status. Women taking a 
supplement prior to pregnancy were more likely to be living in a higher average income 
zip code (F=46.920 p<0.001). Women with a higher average education were also more 
likely to take supplements prior to pregnancy (F=99.233 P<0.001). Age of the woman at 
enrollment was found to be significant (F=31.540 P<0.001). The older women were 
more likely to take a supplement prior to pregnancy. Supplement use prior to pregnancy 
was higher in white, including Hispanic, women as shown in Table 3 (χ2(2)=33.064 
P<0.001). Smoking pack years was also found to be lower in women taking pre-
pregnancy supplements (F=8.832 P<0.003) compared to women who did not take 
supplements. Reproductive history, specifically the number of previous living children, 
was uncorrelated to pre-pregnancy supplement use but trended toward supplement use 
before pregnancy if a woman had previous children (F=3.315 P=0.070). Table 4 
includes variables that were significantly related to pre-pregnancy supplement use.  
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TABLE 3: Supplement Use Prior to Pregnancy with Maternal Race 
n=231   
  Yes (n=116)* No (n=115)* 
White 98 57 
African American 16 56 
Other 2 2 
*P<0.001 using Chi-Square Test 
TABLE 4: Factors Affecting Supplement Use Prior to Pregnancy 
n=231    
  Yes (n=116) No (n=115) P-value 
Income by Zip Code ($) 53,874 39,105 <0.001 
Maternal Education (years) 16 13 <0.001 
Maternal Age at Enrollment 28 24 <0.001 
Smoking Prior to Pregnancy 
 (pack years) 1 2 0.003 
*P values were calculated using a Pearson Chi Square Test 
Note: Income information not available for 4 women;  
1 woman did not report smoking history 
 
We separated supplements taken prior to pregnancy into a number of categories. 
A total of 181 supplements were taken by 116 women. Some women were taking more 
than one supplement prior to pregnancy (Table 5).  
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TABLE 5: 
Supplement Intake Prior to Pregnancy 
n=116 
Multivitamins # of Women 
MVI 42 
Children's MVI 3 
PNV 61 
PNV Rx 8 
Lipids  
Omega 3 - Long Chain and 
Essential Fatty Acid 13 
Independent Vitamins  
Carotene 1 
Folic Acid 5 
Vitamin C 8 
Vitamin D 3 
Vitamin E 4 
Independent Minerals  
Iron 5 
Calcium 9 
Potassium 1 
Zinc 1 
Amino Acids/Protein  
L-Lysine 1 
Spirulina 1 
Herbals  
St. John's Wort 1 
Alfalfa 1 
Bromelain 1 
Herb 2 
Lemon Balm 1 
Olive Leaf Extract 1 
Fenugreek 1 
Microorganism  
Probiotic 1 
Functional Food Extracts  
Grapefruit Seed Extract 1 
Cayenne 1 
Elderberry 1 
Cranberry Extract 3 
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 Five women were taking additional folic acid beyond that provided in a standard 
multivitamin before pregnancy and three continued throughout pregnancy. On average, 
the folate supplement was taken 68 days prior to conception by these 5 women. Data 
was not available for the amount of nutrient the supplement provided.   
Post-natal supplementation 
 Post-natal supplementation was defined as supplement use that continued ≥30 
days after delivery. A total of 104 supplements were consumed post-natally by 82 
women (TABLE 6). Similar to pre-pregnancy supplementation, some women were 
taking more than one supplement.  
TABLE 6: Post-Natal supplement intake 
n=82 
Supplement Name # of Women  % of Women  
Calcium 2 2 
Flaxseed Oil 1 1 
Iron 11 13 
MVI 1 1 
Omega 6 7 
PNV- OTC 54 66 
PNV Rx 27 33 
Vitamin C 2 2 
 
 Women were more likely to take supplements post-natally if they were 
breastfeeding (F=16.546 P<0.001). Post-natal supplementation was associated with 
longer breastfeeding duration (Figure 19). Women still consuming supplements post-
natally had a mean breastfeeding length of 311 days, while the women who stopped 
supplements prior to 30 days postpartum had a mean breastfeeding length of 174 days.  
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Prenatal supplement formulations 
 Supplement formulations varied from brand to brand and over-the-counter (OTC) 
to prescription (Rx). Table 7 outlines the differences in formulations. Sixteen different Rx 
supplements taken by subjects in the study were used in the analysis and 21 OTC 
supplements were used. Three nutrients were found to have statistical significance 
between Rx supplements and OTC supplements. Rx supplements provided significantly 
more folic acid (F=52.973 P<0.001) than OTC supplements and significantly more DHA 
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(F=8.852 P=0.005). Iron was also found to be significantly higher in prescription 
prenatals (F=4.309 P=0.045). 
 
TABLE 7: Comparison of Prenatal Nutrient Contents 
  Rx (n=16) OTC (n=21) P value* 
Vitamin C (mg) 123 110 0.205 
Vitamin D (IU) 351 390 0.174 
Vitamin E (IU) 26 37 0.081 
Folic Acid (µg) 1000 800 <0.001 
Calcium (mg) 179 331 0.073 
Iron (mg) 55 26 0.045 
Iodine (µg) 66 66 0.998 
Choline (mg) 7 1 0.176 
DHA (mg) 132 29 0.005 
*P values were calculated using a one-way ANOVA.
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Chapter 5 
DISCUSSION 
Nutrient intake during pregnancy from prenatal vitamins 
Vitamin C intake from prenatal supplements was found to exceed the RDA for 
pregnancy by 11%. Since vitamin C is a water-soluble nutrient, there is not much 
concern for toxicity. A tolerable upper intake level (UL) has been set at 2 grams 
resulting in gastrointestinal problems such as nausea and diarrhea (24). None of the 
subjects came close to consuming this amount per pregnancy day. In other words, there 
is no concern with the exceeding the RDA by 11%. Gennaro et al (1) found that 79.3% 
of their subjects were not meeting the RDA from diet alone indicating that vitamin C 
intake from supplements is important.  
Mean vitamin D intake from supplements met 55% of the RDA for pregnancy. 
Maximum intake was far from the UL in the subjects. An excess of supplementation 
from vitamin D could lead to potential toxicity evidenced by nausea, headache, weight 
loss and in extreme cases, mineralization of the heart, blood vessels and cutaneous 
tissue (24). Gennaro et al. (1) found that 91.4% of their subjects were not meeting the 
RDA from diet. In combination of diet and supplements, there is a potential deficit in 
vitamin D intake.  
Mean vitamin E intake from prenatal supplements met 100% of the RDA. 
Gennaro et al. (1) found that 98.3% of their subjects were not meeting the RDA through 
diet. This leaves little concern with supplements providing 100% of the RDA because 
many women are not likely to get adequate intake from diet alone. When diet and 
supplementation are combined, it can be inferred that many women are likely to exceed 
the RDA. Vitamin E has been proposed to be one of the least toxic vitamins, so this is 
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not of concern (24). High intakes of vitamin E have been associated with 
gastrointestinal distress, increased bleeding and possible increased risk of respiratory 
infections (24).   
Supplemental folic acid intake exceeded the RDA by 15%. The UL is set at 1mg 
due to insomnia, malaise, irritability, and gastrointestinal distress. Also, excessive folate 
intake can mask potential vitamin B12 deficiency. Zeisel (25) found that during 
development, excessive intake of dietary methyl groups, such as folate, can alter DNA. 
Altered DNA then results in epigenetic changes to gene expression that can be seen 
throughout a lifetime. In pregnant rodent models, high folic acid intake was found to 
alter the coat color of the offspring or result in tail kinking. In humans, it is believed that 
this can be translated to an increased risk of cancer of the offspring. Rett Syndrome has 
also been suggested to result from defective epigenetic regulation.  From dietary intake, 
Gennaro et al. (1), found 89.7% of their subjects were not meeting the folate RDA. 
While excessive folate can result in potential complications, women are not getting 
adequate intake from diet, so supplementation is necessary, but not in excessive 
amounts. While folate fortification in foods has occurred since 1998, Gennaro et al, (1) 
shows that food sources alone are not meeting the needs of pregnant women.  
Calcium intake from prenatal supplements met 17% of the RDA. When assessing 
dietary consumption of pregnant women, Gennaro et al. (1) found that 32.6% of the 
subjects were not getting adequate calcium from the diet. And our study demonstrates 
that pregnant women are not getting sufficient intakes from supplements. Without 
specific nutrient values from diet, it is difficult to determine if supplement use in 
combination with dietary intake would meet the RDA for pregnant women. It has been 
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shown that calcium intake can inhibit iron absorption (26). In pregnancy, iron needs are 
increased, so additional calcium supplements are not recommended beyond the 
average prenatal supplement. In other words, it is imperative to have adequate calcium 
stores prior to conception. Calcium deficiency can result in tetany for the mother and 
may increase the long-term risk of osteoporosis.  
Mean iron intake from supplements met 85% of the RDA. Mean intake from 
supplements was slightly lower than the CDC recommendations of 30 mg/d (9). 
Gennaro et al. (1) found that 82.8% of the women were not meeting the iron needs 
through diet. With the specific amounts from the diet unknown, it is hard to say if 
supplement intake meeting 85% of the RDA is adequate. 
Iodine is thought to be imperative in the production of thyroid hormones (27). 
During pregnancy, a 50% increase in iodine is recommended to meet the thyroid 
hormone need of both the mother and the fetus. Iodine deficiency can result for the 
mother and fetus without adequate intake. Deficiency during pregnancy can result in 
damage to the fetus’ brain development as evidenced by cretinism and ultimately 
mental retardation (27). Of the supplements providing iodine, two formulations 
exceeded the RDA by 32%. Twelve formulations delivered 68% of the RDA by providing 
150 µg and two supplements provided 25 µg, meeting 11% of the RDA.  
While choline requirements are thought to be increased during pregnancy (28), 
0% of the RDA was met through prenatal supplements. Choline is an emerging nutrient 
in pregnancy that has been found to have potential benefits in reducing neural tube 
defects (28). Shaw et al. (28) found decreased risk of neural tube defects with choline 
intake as evidenced by a strong linear association. Deficiency of choline is thought to 
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decrease folic acid metabolism, resulting in an increased risk of neural tube defects. 
Choline is not a common component of prenatal supplements (28), but as research 
continues to be published, it can be expected that prenatal formulations will be altered.  
While DHA does not have an RDA set for pregnancy, much research is being 
conducted on the cognitive benefits on the fetus. While the primary study was a double-
blind, placebo controlled trial using DHA, the amount of DHA from other supplements 
was closely monitored by study personnel. Women were not able to consume more 
than 300 additional mg per day outside of their study capsules. Although this was not an 
initial issue at the beginning of the study, as more research was published regarding the 
benefits of supplementation, the manufacturers of supplements began adding in DHA. 
Prior to this time, some women were taking more than the restricted limit. Research is 
still being conducted to establish an optimal level during pregnancy. Higher maternal 
DHA status during pregnancy has been shown enhanced infant attention in the first year 
of life. Notable differences in the Bayley scores of children at 18 months of age have 
also been recorded in several observational studies, suggesting an increase in cognitive 
abilities in infants whose mothers were supplemented with DHA. Visual acuity at 4 
months of age has been shown to be more mature in infants with mothers with higher 
DHA status (29).  
While this study did not look at dietary intake of the mothers, Gennaro et al. (1) 
examined the dietary intake of pregnant women. Caloric intake was found to be 
excessive, while inadequate micronutrient consumption was reported. All the 
micronutrients examined (iron, folate, vitamin D, vitamin C, vitamin E, and calcium) were 
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all inadequate from the diet, thus showing the importance of prenatal supplementation 
during pregnancy (1).  
Factors affecting supplement intake prior to pregnancy 
 While nearly all of our subjects used supplements during pregnancy, we wanted 
to examine factors that affected supplement use prior to pregnancy. Many studies 
examine use during pregnancy, but since all of our subjects were using supplements we 
were unable to make the same comparisons.  
 Maternal race was found to impact supplementation prior to pregnancy. White 
mothers were more likely to use supplements than African American mothers or other 
races (P<0.001). Suitor et al. found this same finding in pregnant women during 
pregnancy (6), while our study did not find the same result. All of the subjects, no matter 
the race, used supplements during pregnancy.  
 Family income, as determined by zip code, was also found to significantly affect 
supplement use prior to pregnancy (P<0.001). This finding is not surprising considering 
that supplements can be expensive and access may be limited for those with a lower 
income. 
 Maternal education at enrollment was found to be positively associated with 
supplement use prior to pregnancy (P<0001). Women taking supplements prior to 
pregnancy had an average education of 16 years, while women that did not take 
supplements prior to pregnancy had an average education of 13 years. Yu et al. found a 
similar finding in pregnant women with 89.9% of the pregnant women with education 
levels ≥16 years using supplements during pregnancy (5). 
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 Another positive association with supplement use prior to pregnancy was 
maternal age at enrollment (P<0.001). The younger the mother, the less likely she was 
to use supplements prior to pregnancy. The average age for women that did not 
supplement prior to pregnancy was 24, while the average supplemented woman was 28 
years old. Yu et al. had a similar finding in pregnancy, the older the mother, the more 
likely she was to use supplements (5).  
 Smoking status was also negatively associated with supplement use prior to 
pregnancy (P=0.003). Women consuming supplements before pregnancy were less 
likely to smoke than women that did not use supplements. Women using supplements 
before pregnancy had an average pack year consumption of 1, while women not using 
supplements had an average pack year consumption of 2. This finding could be 
contributed to the fact that smokers may be less mindful about health concerns if they 
smoke. Jasti et al. (22) and Yu et al. (5) both found higher adherence in 
supplementation during pregnancy for women that were current smokers.  
 No association was found between supplement use prior to pregnancy and the 
number of previous children (P=0.070). This suggests that if mothers did not take 
supplements with previous children, the women believe there is no benefit to 
supplementation with subsequent pregnancies. 
Supplements taken prior to pregnancy 
 One hundred eighty one supplements were taken by 116 women prior to 
pregnancy. Some of the supplements were the same, while there were many 
supplements taken by only a handful of subjects.  
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 The multivitamin category was made up of adult multivitamins, children’s 
multivitamins, over-the-counter prenatals and prescription prenatals. Almost all of the 
women (n=114) taking a supplement prior to pregnancy were consuming a multivitamin.  
 Long chain and essential fatty acids, such as omega-3, was the next most 
commonly used supplement with 13 women taking the supplement prior to pregnancy.  
Folic acid is recommended to decrease the risk of neural tube defects during 
pregnancy. Only five women (2%) took folic acid prior to pregnancy, as recommended 
by the CDC (9). Average intake was 68 days prior to conception. This could suggest 
that these subjects were purposively attempting to conceive. In order to increase folic 
acid consumption in the United States, grains have been fortified since 1998. As a 
public health initiative, this suggests that not many women of child bearing age are 
consuming folic acid supplements, so the consumption through grains is imperative to 
decrease the risk of neural tube defects.  
 Calcium, as a single nutrient, was taken 8% of our subjects prior to pregnancy, 
lower than the 44% found in the Australian study (7). Specific vitamins used before 
pregnancy included carotene, vitamin C, vitamin D and vitamin E. Independent nutrients 
such as iron, potassium and zinc were also reported. The Australian study found that 
7% of the women used independent zinc supplements during pregnancy (7), although 
this study did not find the same results.  
 Different herbals, microorganisms, amino acids, and functional food extracts 
were reported in limited consumption.  
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Post-natal supplementation 
 Eighty-two women reported taking a supplement at least 30 days after delivery. 
This study found that women were more likely to take a postnatal supplement if they 
were breastfeeding, suggesting that they were trying to improve the quality of their milk 
supply. Women were also found to have a longer mean breastfeeding length if they 
were consuming supplements. Again, suggesting that the quality of the milk was trying 
to be enhanced by supplementation. Of the supplements consumed, the most common 
supplement was a prenatal vitamin, with over-the-counter formulations making up about 
half of the prenatal vitamin consumption.  
Prenatal supplement formulations 
 Since prenatal formulations are not standardized, there is much variation from 
supplement to supplement. Sixteen prescription formulations were averaged to develop 
the prescription formulation and 21 over-the-counter prenatals were averaged to 
develop the over-the-counter formulation. When comparing average prescription 
prenatals to over-the-counter prenatals it was surprising not to find much statistical 
significance in the nutrient amounts. Folic acid content was found in larger amounts in 
prescription supplements (P<0.001). Evidence regarding the benefits of supplementing 
folic acid in pregnancy has been around since the 1980’s, yet over-the-counter 
formulations have not increased to the similar dosage in prescription supplements. Iron 
was also found to be significantly higher in prescription prenatals as (P=0.045). Iron 
recommendations vary greatly, so it is not surprising to find almost a two-fold increase 
in prescription prenatals content.  
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Limitations 
Limitations of this study include the fact that all women had to have the ability to 
swallow capsules, making them more likely to take supplements.  
A major limitation of the study is that there is no diet information provided for 
these women, so we do not know how much of their diet is meeting the RDA.  
The majority of the study population was from KUMC and utilized the on-site 
pharmacy. The majority of the women took the pharmacy generic provided. Also, since 
most subjects were from KUMC, the number of doctors was limited. Doctors often 
prescribed the same prenatal multivitamins to all of their patients.  
Women who took the time to enroll in the study may be more motivated than 
other women, thus increasing their likelihood of taking supplements. 
In order to determine frequency, the most compliant mothers returned the 
monthly questionnaires routinely giving us a better picture of their supplement 
frequency. There were no high risk families enrolled in the study.  
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Chapter 6 
SUMMARY 
 Supplementation during pregnancy appears to be quite widespread, but the 
formulation of supplements is not as consistent. Many women are not meeting the 
RDAs during pregnancy through prenatal supplements. While our study did not 
investigate dietary intake, other studies such as Gennaro et al.(1), suggest that 
pregnant women are not meeting the RDAs through dietary sources either. As a public 
health message, it would be beneficial for formulations of prenatal supplements to be 
standardized to be sure that women are providing necessary nutrients to the developing 
fetus. 
 Formulations should include increased calcium content, as well as choline, iodine 
and DHA. All of the emerging nutrients have been found to be beneficial in pregnancy, 
and thus should be given to the fetus.  
Future directions include assessing not only what supplements women are taking 
during pregnancy, but also diet information to measure what percentage of the women 
are meeting the RDAs for pregnancy. More comprehensive research should be 
conducted on the benefits and levels of the emerging nutrients. Future research could 
also include supplementation outcomes on birth.  
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CONSENT FORM 
 The Effects of DHA on Pregnancy and Infant Outcome 
(Kansas University DHA Outcomes Study or KUDOS) 
 
Sponsor:  NIH (1R01 HD047315) 
 
INTRODUCTION  
As a pregnant woman who is between 8 and 20 weeks of gestation, you are being 
invited to enroll in a research study of a nutrient (DHA) that is a component of normal 
brain and important for brain development. The centers involved in the study are the 
University of Kansas Medical Center in Kansas City, Kansas, St. Luke’s Hospital in 
Kansas City, Missouri,  and Truman Medical Center in Kansas City, Missouri.  If you 
decide to enroll in this study, your baby will participate in research procedures at the 
University of Kansas Medical Center. Dr. Susan Carlson is the main investigator for this 
study.  A total of 350 pregnant women will be enrolled in this study between October 
2005 and January 2010.  
 
You do not have to participate in this research study. It is important that before you 
make a decision to participate, you read the rest of this form. You should ask as many 
questions as you need to understand what will happen if you participate in the study. 
 
BACKGROUND  
Docosahexaenoic acid (DHA) is a fat that is found in very large amounts in the brain. 
DHA is important for how my baby sees and learns. Breast milk and, since 2002, US 
formulas contain DHA.  Many studies have shown that DHA in the diet helps the baby’s 
vision, attention, and ability to learn.  In this way, DHA is considered an important 
nutrient for babies after they are born. 
 
DHA may also be important before babies are born. Four studies found that women’s 
DHA during pregnancy was related to higher infant/child function. These studies are 
called observational studies, meaning that the women’s normal DHA status was studied 
in relation to development of the baby/child. There is only one study that gave women 
DHA during pregnancy and measured development of their babies/children. That study 
showed higher IQ at 4 years of age in children whose mothers took fish oil capsules 
during the last 6 months of pregnancy. (Fish oil contains a lot of DHA). However, 
because women in the study also consumed DHA while they were breastfeeding they 
provided more DHA to their babies after they were born. Therefore, the study does not 
prove that giving DHA before babies are born will help their development. There are no 
studies that have varied DHA intake only during pregnancy.  You and your child are 
being asked to participate in such an experimental study. 
 
PURPOSE 
The purpose of this study is to determine if a dietary supplement of DHA during 
pregnancy will help babies be born at the right time and help their development. If you 
decide to be in the study, you will have a 50-50 chance of receiving capsules with the 
supplement of DHA or ordinary food oil, which does not contain any DHA. 
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PROCEDURES 
If you choose to enroll yourself and your infant in this study, the investigators will record 
some information from your medical record about your pregnancy and medical history. 
They will also ask you a few questions about foods that you usually eat.  You will have a 
blood sample collected from a vein in your arm.  One-half teaspoon of blood will be 
drawn. The blood will be used to measure DHA in your blood as well as other nutrients.  
You will be asked to provide a current address and phone number where you can be 
contacted.  . 
 
During pregnancy:  You will be randomly assigned (like flipping a coin) to capsules 
with DHA-oil or ordinary food oil (which does not contain any DHA). The DHA-oil is the 
same oil that is used in US infant formulas and has been fed safely to millions of infants.  
 
You will be given enough capsules each month to take 3 capsules each day and you 
agree to try to consume all 3 capsules. If you consume all 3 capsules, you will consume 
600 mg of DHA. The capsules are relatively small and you should find them easier to 
swallow than many nutrient supplements. They are orange-flavored, so if you burp 
(common in pregnancy and in the first week of taking any nutrient supplement), the 
taste should not be unpleasant. You do not need to take the capsules at any specific 
time as they are a nutrient and not a drug. However, you should decide upon a regular 
time to take them so that taking the capsules will become a habit and you won’t forget. 
For example, you might wish to take them just before you go to bed or when you have 
your first beverage of the day.  
 
Neither you nor the investigators will know which capsules you have been assigned to. 
On the day you enroll for the study, we will send you home with your first bottle of 
capsules. About 30 days later (early enough so that you do not run out of capsule), you 
will receive another bottle of capsules in the mail. AT THAT TIME, YOU AGREE TO 
PLACE THE FIRST BOTTLE WITH ANY REMAINING CAPSULES IN THE ENVELOPE 
AND DROP IT INTO THE MAIL.   
 
This process will be repeated each month until your baby is born and you will continue 
to take 3 capsules per day until your baby is born. Each time you receive a new bottle, 
you will mail back the bottle that you have been using and that day will open and begin 
using the new bottle.  
 
The investigators will contact you by phone at least once per month. They will ask about 
capsule intake and they will ask how you are doing. Maintaining contact with our study 
personnel on a monthly basis is very important.  
 
IF YOUR PHONE NUMBER OR ADDRESS CHANGES AT ANY TIME DURING THE 
STUDY, YOU WILL LET THE INVESTIGATORS KNOW BY CALLING 913-588-3781 
AND LEAVING A MESSAGE.  
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Delivery:  After you are admitted to the hospital to deliver, you should telephone study 
personnel or ask the person at admitting to telephone them. You will be given a cell 
phone number today to call.  Once you deliver your baby, the investigators will visit you 
in the hospital to collect data about your delivery and your baby’s health.  A sample of 
your baby’s cord blood will be collected after delivery by nurses at the hospital and 
given to the investigators.  A nurse will also draw a small blood sample (one-half 
teaspoon) from you while you are in the hospital. The blood samples will be used to 
measure DHA and other nutrients. The investigators will visit you, and give you an 
appointment for your baby’s first follow-up visit at KUMC. 
 
Visit 1 (6 weeks of age):  The investigators will measure how your baby sees using a 
test that involves placing 3 electrodes directly on your baby’s head. The process 
involves cleaning the area then placing a small amount of paste similar to toothpaste on 
the head. The electrodes are placed on top of the paste. The electrodes will be used to 
record your baby’s brain waves while he/she is looking at pictures. Your child’s weight, 
height and head circumference will be measured again and you will be asked questions 
about what your baby eats.  If you are breastfeeding your baby, you will be asked to 
provide a teaspoon of breast milk to the investigator. The sample will be frozen and 
analyzed for fats that are found in the capsules. The visit should last about 40 minutes. 
You should arrive on time and allow that amount of time for the visit. 
 
Visit 2 (4 months of age): The investigators will measure how your baby sees using 
the same test as before and another vision test. Your baby will wear a pair of plastic 
glasses during the second test. In another test, your child will be given an object to look 
at several times.  The investigator will measure how long he/she looks at the object and 
how quickly he/she stops looking at the object. Your child will be video recorded during 
the test. Your baby’s heart rate will be measured during the test.  Your baby’s height, 
weight and head circumference will be measured and you will be asked about what food 
your baby eats. Your baby will have a blood sample collected by either heel stick or 
drawn from a vein.  If it is necessary to use a heel stick, the investigator may use a 
cream or spray that will numb the area before obtaining the sample.  One-half teaspoon 
of blood will be drawn. The blood will be used to measure DHA and other nutrients. You 
should let the investigator know if your baby has been sick or not acting well since 
his/her last visit.  The visit will take 60-90 minutes.  
 
Visit 3 (6 months of age): The investigators will measure how your baby sees using 
the test that requires him/her to wear a pair of plastic glasses. In another test, he/she 
will be given an object to look at several times (just like at 4 months of age).  The 
investigator will measure how long he/she looks at the object and how quickly he/she 
stops looking at the object. Your child will be video recorded during the test. Your baby’s 
heart rate will be measured during the test.  Your baby’s height, weight and head 
circumference will be measured.   You will be asked questions about what your baby 
eats.  You should let the investigator know if your baby has been sick or not acting well 
since his/her last visit.  The visit should take 40 -60 minutes.  
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Visit 4 (9 months of age):  Your baby will have both tests that measure how he/she 
sees. In another test, your child will be given an object to look at several times (just like 
at 4 and 6 months of age).  The investigator will measure how long he/she looks at the 
object and how quickly he/she stops looking at the object and your baby’s heart rate will 
be measured during the test. Your child will be video recorded during the test. Your 
baby’s height, weight and head circumference will be measured. You will be asked 
questions about what your baby eats.  You should let the investigator know if your baby 
has been sick or not acting well since his/her last visit. The visit should take about 40-60 
minutes.  
 
Visit 5 (10 months of age):  During this visit your baby will be placed on your lap in 
front of a small table.  A test will be completed with a small toy, foam block and 2 cloths 
that will be placed in front of your child. You will also take a short language test. The 
small toy will be given to your child to keep. In another test, your baby will be asked to 
take turns with the researcher building fun toys. After your baby has played for a 
moment with the pieces, the researcher will show him or her how to build the toy. Then, 
your baby will be given a turn to put the toy together. Your baby’s turn will happen either 
immediately or after 10-minutes of play with other things.  Your child will be video 
recorded during the tests.  You should let the investigator know if your baby has been 
sick or not acting well since his/her last visit.  You will be asked questions about what 
your baby eats. The entire 10-month visit should last 65 - 70 minutes.  
 
Visit 6 (12 months of age):  The investigators will measure how your baby sees using 
both vision tests. Your child will be video recorded while playing with an interesting toy 
and the investigator will use the recording to measure some aspects of attention.   Your 
child’s height, weight and head circumference will be measured.   You will be asked 
questions about what your baby eats.  You should let the investigator know if your child 
has been sick or not acting well since his/her last visit.  The visit should take about 2 
hours.  It is important that your child be rested before the testing at this visit. If for some 
reason your baby cannot finish the tests that day – this may happen if he/she is 
unusually fussy or tired – you will be asked to return to finish the remaining tests within 
7 days.  
 
Visit 7 (18 months of age):  The investigators will measure how your child sees using 
the test that he/she had while wearing plastic glasses.  Your child will be video recorded 
while playing with an interesting toy and the investigator will use the recording to 
measure some aspects of attention. Your child will also be given a standardized test to 
measure mental and physical development. Your child’s height, weight and head 
circumference will be measured. You will be asked questions about what your baby 
eats.  You will be asked questions about the words your child uses and understands.   
You should let the investigator know if your child has been sick or not acting well since 
his/her last visit.  The visit should take about 2 hours.  It is important that your child be 
rested before the testing at this visit. If for some reason your child cannot finish the tests 
that day – this may happen if he/she is unusually fussy or tired – you will be asked to 
return to finish the remaining tests within 7 days.  
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RISKS 
Some redness, soreness, or bruising may occur at the site of blood sampling.  There is 
also a very slight risk of infection.  
 
You may experience burping from the capsules and find this unpleasant 
 
There are no known risks of consuming the amount of DHA you will be provided if you 
receive the DHA. Even if you forget to take your capsules for one or two days, there is 
no known risk of deciding to “catch up” on the third day. The amount is smaller than 
pregnant women in many countries eat every day. Nevertheless, you could develop a 
problem that has not been observed before. 
 
NEW FINDINGS STATEMENT 
You will be informed if any significant new findings develop during the course of the 
study that may affect your willingness to participate or to allow your child to participate 
in this study. 
 
BENEFITS 
You and your child may or may not benefit from participating in this study. If you receive 
the supplement, it may help your baby to be born at the right time and your 
baby’s/child’s development. If you will not get the supplement, your baby and you will 
not be getting any of those benefits. It is also possible that all infants/children will get 
some benefit from being followed closely with developmental testing. It is hoped that 
additional information gained in this research study may be useful in understanding if 
DHA can help your baby be born at the right time and help your baby’s vision, attention, 
and learning as he or she grows. You will receive a video recording of your infant doing 
the 4, 6, and 9 month looking test when the 12 month visit is complete. 
 
ALTERNATIVES 
You do not have to participate in this study to be able to take DHA supplements while 
you are pregnant. You may purchase capsules containing DHA at local stores without a 
prescription (for example, Osco, Costco, Wal-Mart). There are also several brands of 
prenatal supplements with DHA available by prescription or over the counter.  The 
prenatal capsules typically contain 200 mg of DHA each and are marketed to take one 
capsule/day as a DHA supplement.  
 
COSTS 
Capsules containing either DHA or food oil will be provided to you at no cost while you 
are participating in this study.  You will not incur any costs because of your or your 
child’s participation  
 
PAYMENT TO SUBJECTS 
If study investigators are able to communicate with you each month you will be given 2 
bonus gift cards to either Wal-Mart or Target of $25 each. The first gift card will be given 
to you half way through your treatment phase if communication is maintained at least 
one time each month during the first half of your treatment. The second gift card will be 
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given at delivery if communication maintained at least one time each month during the 
second half of your treatment.  
 
Additionally, if the study investigators are called after you are admitted for delivery you 
will be given your choice of a bonus gift card worth $50 from either Wal-Mart or Target. 
You may make the call yourself or have someone else call for you. Study personnel will 
give you the gift card when they come to the hospital after your baby is born.   
 
Once your baby is born, you will receive a check for $50 after your baby completes 
each of the following visits: 6 weeks, 4 months, 6 months, 9 months, and 10 months. 
You will receive a check for $100 after your child completes each of the following visits: 
12 and 18 months. The reimbursements are to cover the costs of transportation and to 
partially compensate you for your time required to participate in the study.  
 
Your name, address, social security number, and the title of this study will be given to 
the KUMC Research Institute.  This is done so that the Research Institute can write a 
check for study payments.  Payments are taxable income. 
 
IN THE EVENT OF INJURY 
In the event you experience any serious health problem (hospitalization, life-threatening 
illness, or death) for any reason during your pregnancy, you should immediately seek 
treatment or help in the way you normally would as if you were not in a study. You 
should let Susan Carlson, Ph.D. know about any of these problems as soon as possible 
by calling her office (913-588-5359) or the study office (913-588-3781). A message may 
be left at both numbers.  Dr. Carlson may also be reached at home (816-960-1805). 
 
INSTITUTIONAL DISCLAIMER STATEMENT 
If you believe you have been injured as a result of participating in research at Kansas 
University Medical Center (KUMC), you should contact the Director, Human Research 
Protection Program, Mail Stop #1032, University of Kansas Medical Center, 3901 
Rainbow Blvd., Kansas City, KS 66160.  Compensation to persons who are injured as a 
result of participating in research at KUMC may be available, under certain conditions, 
as determined by state law or the Kansas Tort Claims Act.  
 
Truman Medical Center (TMC) will provide medical attention to you if you suffer any 
injury or harm as a direct result of participating in this research project. TMC, your study 
doctor, and the sponsor of this study will decide, at their discretion, who should pay for 
the medical care. TMC will provide treatment to you in the event of any medical 
emergency while present at TMC, whatever the cause. Moreover, you will have the 
benefit of the coverage of any existing healthy insurance you own. Participation in this 
research study does not take the place of routine physical examinations or clinic visits to 
your person physician. If you believe you have been injured as a result of participating 
in this study you are encouraged to contact the study investigator, Dr. Susan Carlson, at 
her work number, 913-588-5359. 
 
The University of Missouri-Kansas City appreciates the participation of people who help 
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it carry out its function of developing knowledge through research. Although it is not the 
University’s policy to compensate or provide medical treatment for persons who 
participate in studies, if you think you have been injured as a result of participating in 
this study, please call the investigator, Dr. Susan Carlson at 913-588-5359 (work) or 
Sheila Anderman, IRB administrator of UMKC’s Adult Health Sciences Institutional 
Review Board at 816-235-6150 
 
CONFIDENTIALITY AND PRIVACY AUTHORIZATION 
Names of subjects or information identifying subjects will not be released without written 
permission unless required by law.  Videotapes of your baby when he/she is looking at 
pictures and playing with toys will be used only by the investigators and their students 
and to make a videotape copy for you.  The videotapes will be secured under lock and 
key like all other information that could be linked directly to your child. The videotape of 
your child will not be shown without specific permission from you and even then would 
not identify your child by name.  Efforts will be made to keep you and your child’s 
personal information confidential.  Researchers cannot guarantee absolute 
confidentiality.  If the results of this study are published or presented in public, 
information that identifies you and/or your baby will be removed.  
 
The privacy of you and your child’s health information is protected by a federal law 
known as the Health Insurance Portability and Accountability Act (HIPAA).  If you 
choose to participate in this study, you will be asked to give permission for researchers 
to use and disclose your and your baby’s health information that is relevant to the study.    
 
To perform this study, researchers will collect health information about me and my child 
from his/her and my medical records and from the study activities that are listed in the 
Procedures section of this consent form.  My and my baby’s study-related health 
information will be used at KU Medical Center by Dr. Carlson, members of the research 
team, Truman Medical Center, St. Luke’s Hospital and the KU Hospital Medical Record 
Department. The KUMC Research Institute as well as officials at Truman Medical 
Center and St. Luke’s Hospital that oversee research, including the KUMC Human 
Subjects Committee, the IRB that governs Truman Medical Center and St. Luke’s 
Hospital and other committees and offices that review and monitor research studies, 
may also see my and my baby’s study-related health information.  
 
Dr. Carlson and her team may share information about me and my baby with 
representatives of Martek Biosciences, the monitoring company who verifies study data, 
the laboratory that processes study lab samples, other business partners who help with 
the study, the U.S. Food and Drug Administration (FDA), and U.S. agencies that govern 
human research (if and when regulatory compliance issues arise). Martek Biosciences 
(Columbia, MD) donated the capsules for this study that is otherwise supported by the 
National Institute of Child Health and Human Development.   
 
Some of the persons or groups that receive my and my baby’s study information may 
not be required to comply with HIPAA privacy laws.  My and my child’s information may 
lose its federal protection if those persons or groups disclose it.   
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Permission granted on this date to use and disclose my health information remains in 
effect indefinitely.  By signing this form I give permission for the use and disclosure of 
my and my child’s information for purposes of the study at any time in the future. 
 
If I enroll in the study, the investigators cannot tell me what capsule I was assigned to 
until the study ends. This may be after I have stopped taking the capsules. 
 
QUESTIONS 
I have read the information in this form. Dr. Carlson or her associates have answered 
my question(s) to my satisfaction.  I know if I have any more questions after signing this 
I may contact Dr. Carlson or one of her associates at (913) 588-5359.  If I have any 
questions about my or my child’s rights as a research subject, I may call (913) 588-1240 
or write the Human Subjects Committee, University of Kansas Medical Center, 3901 
Rainbow Blvd. MSN 1032, Kansas City, KS 66160. 
 
SUBJECT RIGHTS AND WITHDRAWAL FROM THE STUDY 
My and my child’s participation in this study is voluntary and the choice to not participate 
or to quit at any time can be made without penalty or loss of benefits.  Not participating 
or quitting will have no effect upon the medical care of treatment my child receives now 
or in the future at the University of Kansas Medical center.  The entire study may be 
discontinued for any reason without my consent by the investigator conducting the 
study, by the sponsor of the study, or the FDA.  My child’s participation can be 
discontinued by the investigator or by the sponsor if it is felt to be in my child’s best 
interest or if I do not follow the study requirements.  If I choose to withdraw before my 
child is 18 months of age, I may be asked to answer questions about the study on the 
telephone. 
 
If I want to cancel permission to use my or my child’s health information, I should send a 
written request to Dr. Carlson.  The mailing address is Susan Carlson, Ph.D., Dept. of 
Dietetics and Nutrition, MS 4013, 4019 Delp, University of Kansas Medical Center, 3901 
Rainbow Boulevard, Kansas City, KS 66160. If I cancel permission to use my child’s 
health information, the research team will stop collecting any additional information 
about me and my child. 
 
Should the study be terminated prior to the completion of my pregnancy, neither the 
investigator nor the University of Kansas Medical Center will be under any obligation to 
provide me with DHA capsules used in the study.  
 
CONSENT 
Dr. Carlson or her associates have given me information about this research study.   
They have explained what will be done and how long it will take.  They explained the 
inconvenience, discomfort and risks that may be experienced during this study.   
 
By signing this form, I give my permission for my and my child’s health information to be 
used and disclosed for the purposes of this research study.  If I choose not to sign this 
form, my child and I will not be able to participate in the study.   
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I voluntarily consent to my and my child’s participation in this research study.  I have 
read the information in this form and have had an opportunity to ask questions and have 
them answered.  I will be given a copy of the signed form to keep for my records. 
 
___________________________________    
Type/Print Subject's Name       
____________________________________ _______ __________________ 
Signature of Subject       Time   Date 
____________________________________ 
Type/Print Name of Person Obtaining Consent 
____________________________________   __________________ 
Signature of Person Obtaining Consent     Date 
__________________________________ 
Type/Print Name of Principal Investigator 
____________________________________   __________________ 
Signature of Principle Investigator      Date 
 
 
May the investigators contact you after the study is over to ask if you interested in 
continuing your child’s participation?  If you agree to be contacted, the investigators 
would explain any new study to you later and you would have the chance to decide if 
you wanted to participate at that time (please circle your response). 
 
Yes 
 
No  
 
____________________________________    
Type/Print Subject's Name       
____________________________________ _______ __________________ 
Signature of Subject       Time   Date 
____________________________________ 
Type/Print Name of Person Obtaining Consent 
____________________________________   __________________ 
Signature of Person Obtaining Consent     Date 
____________________________________ 
Type/Print Name of Principal Investigator 
____________________________________   __________________ 
Signature of Principle Investigator              Date 
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APPENDIX B 
CASE REPORT FORM 
SUPPLEMENT USE AT ENROLLMENT 
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SUPPLEMENT INTAKE DATA 
PATIENT 
NUMBER 
PATIENT 
INITIALS 
DATE 
   
 
 
Ethnicity 
(Check one box) 
o African-American  
o Asian-American 
o Hispanic  
o European-American (other than 
Hispanic):  
o Other_____________________ 
 
Initial Hgb (at 1st OB appt):_________ 
 
2nd Hgb (at 28 week lab):__________ 
 
Date:___________________ 
 
Date:___________________ 
 
Was an additional iron supplement 
prescribed during pregnancy? 
ο yes  ο no  
Date:___________________ 
Separate iron supplements taken 
during pregnancy 
ο yes  ο no  
If yes, frequency: ______________________ 
Prenatal Vitamins taken during 
pregnancy 
*if just prescribed, complete at subsequent visit 
or by phone interview 
ο yes  ο no  
If yes, name of supplement:    ____________ 
 
Approximate date started:  ______________ 
 
Gestational Age at start of intake:_________ 
 
Intake frequency: ______________________ 
Was an additional DHA supplement 
taken during pregnancy? 
ο yes  ο no  
If yes, name of supplement: ______________  
 
Dose:________    Start Date:______________ 
Vitamin supplements  
prior to pregnancy 
ο yes  ο no  
If yes, what: _______________________ 
Other nutritional supplements 
prior to pregnancy 
ο yes  ο no  
If yes, what: _______________________ 
 
 
Date enrolled:  ______/_____/_____ 
                mmm/dd/yyyy 
 
Age Group – (check one) 
 
16 – 25.99    Group I   _______      26 – 35.99 Group II _________ 
 
 
Date of Initial Capsule Dispensing:   ____/_____/_____ 
                           mmm/dd/yyyy  
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APPENDIX C 
SUPPLEMENT USE AT 6 WEEK POST-NATAL VISIT 
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PROTOCOL FORM ID
HSC #10186 D
BEFORE PREGNANCY
 Multivitamin/Prenatal  Iron
Name  ________________________ Name  ________________________
Dosage  _________________________ Dosage  _________________________
Amount taken ________________________ Amount taken ________________________
Date/Year Started ______________________ Date/Year Started ______________________
Stop Date, if applicable __________________ Stop Date, if applicable __________________
 Calcium  Other
Name  ________________________ Name  ________________________
Dosage  _________________________ Dosage  _________________________
Amount taken ________________________ Amount taken ________________________
Date/Year Started ______________________ Date/Year Started ______________________
Stop Date, if applicable __________________ Stop Date, if applicable __________________
DURING PREGNANCY
 Multivitamin/Prenatal  Iron
Name  ________________________ Name  ________________________
Dosage  _________________________ Dosage  _________________________
Amount taken ________________________ Amount taken ________________________
Date/Year Started ______________________ Date/Year Started ______________________
Stop Date, if applicable __________________ Stop Date, if applicable __________________
 DHA (other than study capsules)  Other
Name  ________________________ Name  ________________________
Dosage  _________________________ Dosage  _________________________
Amount taken ________________________ Amount taken ________________________
Date/Year Started ______________________ Date/Year Started ______________________
Stop Date, if applicable __________________ Stop Date, if applicable __________________
INVESTIGATOR RANDOM CODE
CARLSON
NUTRITIONAL SUPPLEMENT USE
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 INVESTIGATOR PROTOCOL  RANDOM CODE  
FORM 
ID 
 CARLSON HSC #10186     D 
           
NUTRITIONAL SUPPLEMENT USE, CONTINUED 
           
AFTER PREGNANCY        
 Multivitamin/Prenatal  Iron      
 Name  ________________________ 
Name  
________________________  
 Dosage  _________________________ Dosage  _________________________ 
 Amount taken ________________________ Amount taken ________________________ 
 Date/Year Started ______________________ 
Date/Year Started 
______________________ 
 Stop Date, if applicable __________________ 
Stop Date, if applicable 
__________________ 
           
 DHA     Other      
 Name  ________________________ 
Name  
________________________  
 Dosage  _________________________ Dosage  _________________________ 
 Amount taken ________________________ Amount taken ________________________ 
 Date/Year Started ______________________ 
Date/Year Started 
______________________ 
 Stop Date, if applicable __________________ 
Stop Date, if applicable 
__________________ 
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APPENDIX D 
MAILED MONTHLY SUPPLEMENT USE QUESTIONNAIRE 
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Prenatal Supplement Questionnaire 
Subject ID______ 
 
 
 
Dear Study Participant, 
 
 Part of our study requires that we keep track of all vitamins and/or supplements that you 
may take during pregnancy.  We do not want to influence the type of supplements you take nor 
tell you how often you should take non-study supplements.  If you have questions about your 
vitamin/supplement intake you should ask your doctor.  Instead, we would like an idea of your 
daily supplement routine. 
 
 It is especially important that we know the exact kind of supplement(s) you take.  You 
may have a prescription from your doctor or a bottle you purchased from the store.  Regardless 
of where it came from, we ask that you look at the bottle and write down exactly what the label 
says.  Also, if you are not taking any vitamins or supplements at this time because of nausea, 
vomiting, or any other reason, that’s fine too – we’d just like to be able to make note of it. 
 
Listed below are several situations.  Please pick the statement(s) that best describes your 
situation for the past month and fill in the blanks.  Also, because you will be returning your 
study bottle there is no need to write down information about your study capsules unless there is 
something unique you’d like to add.  After you have filled in the appropriate blanks, please 
return this letter with your bottle.  If you have any questions, call my office (913.588.3781).  I’m 
always willing to help! 
 
 
1)  I am not taking a prenatal vitamin at this time because: 
________________________________________________________________________ 
2)  I am taking a prenatal vitamin.  The name of the vitamin is: ______________________.  
I got my vitamin from: _______________________.  In the past week I’ve taken my 
vitamin _______ time(s).   
3)  I am taking other supplements.  The name of the supplement(s) is/are: 
_________________________________________________________________. In the 
past week I’ve taken this supplement(s) _______ time(s).   
PS—I will be sending this same questionnaire every month with your new bottle so we can 
keep track of any changes that occur. 
